Patent ID: 7235258

Claim:
An oral sustained-release pharmaceutical composition comprising a core matrix comprising a therapeutically effective amount of an active compound, a gelling agent, and a polymeric film coating material comprising a mixture of ethyl cellulose and hydroxypropyl methylcellulose that retards access of liquids to the active compound and/or retards release of the active compound through the film-coating, wherein the amount of the active compound represents from about 40% to about 70% by weight of the oral-sustained release pharmaceutical composition, and wherein the active compound is selected from the group consisting of: isovaleric acid, a pharmaceutically acceptable salt of isovaleric acid, a pharmaceutically acceptable ester of isovaleric acid, a compound having the structure: wherein A=H, CH 3 , or OH, B=H, OH, or CH 3 , X=CH 2 , CHCH 3 , C(CH 3 ) 2 , —O—, CH(OH), or —CH 2 O—, and a compound selected from the group consisting of isovaleramide, 2-methylisovaleramide, 3-methylisovaleramide, 2,2-dimethylisovaleramide, 2,3-dimethylisovaleramide, 4-methylisovaleramide, 2,4-dimethylisovaleramide, 3,4-dimethylisovaleramide, 2,2,4-trimethylisovaleramide, 3-hydroxyisovaleramide, 4-hydroxyisovaleramide, 4-hydroxy-3-methyl-isovaleramide, 2-hydroxyisovaleramide, N-(2-acetamido)isovaleramide, 2-methyl-1-propylsulfonamide, 1-methylethyl sulfamate, 2-methyl-1-propyl sulfamate, isopropyl carbamate, and isobutylcarbamate.